28 Fuxing Road, Beijing, 100853 China. E-mail: hanwdrsw@sina.com or hanwdrsw69@yahoo.com Received 3 May 2014; Accepted 25 August 2014 Accepted article preview online 1 September 2014; Advance online publication 23 September 2014 We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia .
http://ift.tt/1DeFErS
http://ift.tt/1DeFErS
No comments:
Post a Comment